Navigation Links
New Anti-Clotting Drug May Work Better After Hip Replacement
Date:12/23/2010

By Jenifer Goodwin
HealthDay Reporter

WEDNESDAY, Dec. 22 (HealthDay News) -- A new drug, apixaban, may be better for preventing dangerous blood clots in the legs and lungs after hip replacement surgery than a commonly used older drug, a new study finds.

Researchers in Denmark compared the two anti-clotting drugs in a head-to-head test involving about 5,400 hip replacement patients.

About 3.9 percent of patients given the older drug, enoxaparin, developed venous thromboembolism (clot in the legs), a pulmonary embolism (clot in the lungs) or died after the surgery, according to the study.

That compares to only 1.4 percent of patients given apixaban.

Apixaban is being developed by Bristol-Myers Squibb and Pfizer, which funded the Phase III trial reported in the Dec. 23 issue of the New England Journal of Medicine.

The company has applied to the U.S. Food and Drug Administration for drug approval and expects to complete the application process in the first quarter of 2011, said Christina Trank, associate director of public affairs for Bristol-Myers Squibb, headquartered in New York City.

Sanofi-Aventis makes the older drug, enoxaparin (Lovenox).

"The apixaban was superior to enoxaparin, including the total number of patients with thromboembolism and major embolism," said lead study author Dr. Michael Rud Lassen, a spine surgeon and clinical researcher at Horsholm Hospital at the University of Copenhagen.

Deep vein thrombosis is one of the most common complications after lower extremity surgery, including hip and knee replacement, explained Dr. Richard Stein, a professor of cardiology at New York University School of Medicine and a spokesman for the American Heart Association.

Clots can form in the veins of the legs, leading to chronic swelling, and a piece of the clot can break off and travel to the lungs, forming a pulmonary embolism, which can be fatal.

After hip replacement, patients typically receive (warfarin) Coumadin, a blood thinner that inhibits clotting. But Coumadin takes a day or more to kick in, so patients usually are immediately put on enoxaparin, Stein added.

There are several drawbacks to that strategy. Enoxaparin is delivered by injection, whereas apixaban can be taken in oral form.

Coumadin can be somewhat unpredictable and patients taking it have to be monitored, Stein said.

"It often is difficult to find the right dosage. Sometimes we overshoot and patients are at risk of bleeding, and sometimes we undershoot and they are at risk of getting the clot in their vein," Stein said.

The new drug seemed to reduce clots by nearly half and resulted in slightly fewer problems with bleeding at the surgical site, Stein said.

"This is an important article," Stein said. "They showed a reduction in bleeding and a reduction in major and minor complications, including deep vein thrombosis, non-fatal pulmonary embolism or cardiac death, which usually means fatal pulmonary embolism. They showed those risks were reduced substantially in the group taking the apixaban compared to the enoxaparin group."

Apixaban is also being studied for use after knee replacement surgery and for patients with atrial fibrillation, among other conditions. In addition to the hip replacement study, there are eight other completed or ongoing Phase III clinical trials involving the drug, Trank said.

Apixaban is one of several drugs under development that work by inhibiting factor Xa in the blood, according to an accompanying editorial that predicts a huge impact if the drug is "conscientiously priced."

Bristol-Myers Squibb declined to provide information about the cost of the drug.

More information

The U.S. National Heart, Lung, and Blood Institute has more on deep vein thrombosis.

SOURCES: Michael Rud Lassen, M.D., spine surgeon and clinical researcher, Horsholm Hospital, University of Copenhagen, Copenhagen, Denmark; Richard Stein, M.D., professor of cardiology, New York University School of Medicine, New York City; Christina Trank, associate director, public affairs, Bristol-Myers Squibb, New York City; Dec. 23, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Extended use of anti-clotting drug helps some bedridden patients
2. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
3. Memo to Men: To Live Longer, Take Better Care of Your Body
4. Do Breast-Fed Baby Boys Grow Into Better Students?
5. Rash Due to Lung Cancer Drug May Be Linked to Better Survival
6. PSA test better predicts cancer in men taking prostate-shrinking drug
7. New survey device gets better information on teenage sexual behavior
8. Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows
9. UTHealth study suggests private insurers control health care spending better than Medicare
10. Good grades in high school lead to better health, study finds
11. Cognitively-impaired human research subjects need better protection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Anti-Clotting Drug May Work Better After Hip Replacement
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
Breaking Medicine Technology: